Bortezomib for desensitization of patients on a waiting list for deceased donor kidney transplant: experience in Mexico City.

Highly sensitized patients represent a challenge in all transplant programs. The use of bortezomib in combination with other strategies could be a real option for some patients. Unfortunately, one single cycle of four doses of bortezomib with 3 PP sessions may not be sufficient. With all the agents available to use in desensitization it is still not clear what is the best combination or who are the best candidates. We need more time and experience with its use to identify which patients could be the best candidate to receive it for desensitization.